Home Cart Sign in  
Chemical Structure| 1570496-34-2 Chemical Structure| 1570496-34-2

Structure of IACS-010759
CAS No.: 1570496-34-2

Chemical Structure| 1570496-34-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IACS-010759 is an orally effective inhibitor of mitochondrial oxidative phosphorylation complex I (OXPHOS). IACS-010759 inhibits proliferation and induces apoptosis in OXPHOS-dependent brain cancer and acute myeloid leukemia (AML) models. IACS-010759 has potential for research in relapsed/refractory AML and solid tumors.

Synonyms: IACS-10759

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of IACS-010759

CAS No. :1570496-34-2
Formula : C25H25F3N6O4S
M.W : 562.56
SMILES Code : FC(F)(F)OC1=CC=C(C2=NOC(C3=NN(CC4=CC=CC(N5CCC(S(=O)(C)=O)CC5)=C4)C(C)=N3)=N2)C=C1
Synonyms :
IACS-10759
MDL No. :MFCD30489429
InChI Key :HWJWNWZJUYCGKV-UHFFFAOYSA-N
Pubchem ID :86711931

Safety of IACS-010759

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
FL5.12 cells, MYC-overexpressing B-cell lines 135 nM 48 h The purpose of this experiment was to assess the cytotoxic effect of IACS-010759 in MYC-overexpressing cells. The results indicated that ascorbate potentiated the pro-oxidant and antitumoral effects of IACS-010759. PMC10245039
THP-1 cells 5 µM 72 hours Inhibition of complex I with IACS-010759 resulted in markedly decreased growth for cells expressing IDH1 R132H, but not for those expressing IDH2 R140Q. PMC9098909
KELLY cells 10 mM and 100 mM 24 hours IACS-010759 significantly suppressed the oxygen consumption rate (OCR) in KELLY cells, indicating its inhibition of OXPHOS. PMC8577318
SK-N-BE(2) cells 10 mM and 100 mM 5 days IACS-010759 significantly suppressed the growth of SK-N-BE(2) cells and induced apoptosis. PMC8577318
SK-N-DZ cells 10 mM and 100 mM 5 days IACS-010759 significantly suppressed the growth of SK-N-DZ cells and induced apoptosis. PMC8577318
SK-N-FI cells 10 mM and 100 mM 5 days IACS-010759 significantly suppressed the growth of SK-N-FI cells and induced apoptosis. PMC8577318
SK-N-SH cells 10 mM and 100 mM 5 days IACS-010759 had a weaker inhibitory effect on the growth of SK-N-SH cells and did not significantly induce apoptosis. PMC8577318
T-ALL cells 0-123 nM 96 hours IACS-010759 causes potent growth inhibition through induction of metabolic shut-down and redox imbalance in NOTCH1-mutated T-ALL cells. PMC9120040
MCF7 LTED cells 4.7 nM 72 hours To evaluate the sensitivity of endocrine therapy and CDK4/6 inhibitor-resistant cells to IACS-010759, results showed that MCF7 LTED cells were more sensitive to IACS-010759. PMC10349040
MCF7 PalboR cells 0.6 nM 72 hours To evaluate the sensitivity of endocrine therapy and CDK4/6 inhibitor-resistant cells to IACS-010759, results showed that MCF7 PalboR cells were more sensitive to IACS-010759. PMC10349040
H1299 cells 100nM 24-48 hours To evaluate the growth inhibitory effect of IACS-010759 on SMARCA4 deficient cells, results showed that SMARCA4 reconstitution significantly restored cell viability. PMC6650267
A549 cells 100nM 24-48 hours To evaluate the growth inhibitory effect of IACS-010759 on SMARCA4 deficient cells, results showed that SMARCA4 reconstitution significantly restored cell viability. PMC6650267
H2030 cells 100nM 24-48 hours To evaluate the growth inhibitory effect of IACS-010759 on SMARCA4 deficient cells, results showed that SMARCA4 reconstitution significantly restored cell viability. PMC6650267
H460 cells 0.63, 1.25, 2.5, 5.0, 10, and 20 mM 72 hours To evaluate the synergistic effect of IACS-010759 with trametinib, the results showed that the combination produced a strong synergy (CI <0.7) in H460 cells. PMC10031260
Calu-1 cells 0.63, 1.25, 2.5, 5.0, 10, and 20 mM 72 hours To evaluate the synergistic effect of IACS-010759 with trametinib, the results showed that the combination produced a strong synergy (CI <0.7) in Calu-1 cells. PMC10031260
H441 cells 0.63, 1.25, 2.5, 5.0, 10, and 20 mM 72 hours To evaluate the synergistic effect of IACS-010759 with trametinib, the results showed that the combination produced a strong synergy (CI <0.7) in H441 cells. PMC10031260

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice OC-PDX models Oral 7.5 mg/kg 5 days on/2 off To evaluate the therapeutic effects of IACS-010759 on tumor progression. PMC9359716
CD1 nude mice and NSG mice lymphoma xenografts Oral Gavage and Intraperitoneal injection 1 or 2.5  mg/kg Daily doses until tumor progression was measured The purpose was to determine the in vivo antitumor efficacy of IACS-010759 in combination with ascorbate. The results showed significant tumor regression in the double-treated groups. PMC10245039
Zebrafish MYCN-driven neuroblastoma model 100 nmol/L 96 hours IACS-010759 significantly suppressed the growth of MYCN-driven neuroblastoma in zebrafish models. PMC8577318
Mice Notch1-mutated T-ALL model Oral 5 mg/kg 5 days per week for 5 weeks IACS-010759 significantly delayed leukemia progression and extended survival in a Notch1-mutated T-ALL mouse model. PMC9120040
Mice ER+ breast cancer PDX models Oral 10 mg/kg 5 days per week for 50 days To evaluate the anti-tumour activity of IACS-010759 in ER+ breast cancer PDX models, results showed that IACS-010759 significantly inhibited tumour growth. PMC10349040
Mice Intracranial melanoma xenograft model Oral 5 mg/kg Once daily for 42 days IACS-010759 significantly improved survival in mice bearing intracranial melanoma xenografts and inhibited brain metastasis formation in the spontaneous brain metastasis model. PMC6497554
Mice KPS tumor model Oral 7.5mg/kg once daily for a total of three weeks To evaluate the in vivo anti-tumor efficacy of IACS-010759 on KPS tumors, results showed that IACS-010759 significantly inhibited the growth of KPS tumors. PMC6650267
C57BL/6 and BALB/cA Nude mice H460 xenograft model Oral 5 mg/kg Once daily for 21 days To evaluate the inhibitory effect of IACS-010759 combined with trametinib on H460 xenograft tumors, the results showed that the combination significantly inhibited tumor growth and prolonged mouse survival. PMC10031260
129Sv/Ev mice PD-1 resistant and PD-1 sensitive 344SQ NSCLC adenocarcinoma xenograft models Oral 7.5 mg/kg Once daily until the endpoint To evaluate the antitumor effect of IACS-010759 in combination with radiotherapy, results showed that in the PD-1 resistant model, IACS-010759 significantly inhibited tumor growth and combined therapy increased local control PMC7319777

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.89mL

1.78mL

0.89mL

17.78mL

3.56mL

1.78mL

References

 

Historical Records

Categories